---
title: "BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292231004.md"
description: "BeyondSpring highlighted plinabulin's potential in non-squamous NSCLC following PD-1/L1 inhibitor progression. The DUBLIN-3 Phase 3 trial demonstrated a median overall survival of 10.5 months versus 9.4 months for docetaxel (HR 0.82, p=0.0399), with significantly reduced grade 4 neutropenia. A mechanism-enriched subset showed improved survival (HR 0.55). The company plans the confirmatory DUBLIN-4 Phase 3 trial targeting post-PD-1/L1 patients."
datetime: "2026-07-09T18:18:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292231004.md)
  - [en](https://longbridge.com/en/news/292231004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292231004.md)
generator: "portal-rs"
---

# BeyondSpring posts corporate presentation spotlighting plinabulin immune-modulating cancer therapy pipeline

-   BeyondSpring outlined late-stage plans for plinabulin, positioning it for non-squamous NSCLC following PD-1/L1 inhibitor progression. \* DUBLIN-3 Phase 3 (n=559) showed OS HR 0.82; median OS 10.5 months vs 9.4 months for docetaxel; p=0.0399. \* Grade 4 neutropenia fell to 22.3% from 43.5% across cycles; exposure-adjusted grade 4 event rate RR 0.55; p<0.0001. \* Mechanism-enriched post-hoc subset showed median OS 15.8 months vs 11.7 months; OS HR 0.55. \* Planned DUBLIN-4 confirmatory Phase 3 targets post-PD-1/L1 non-squamous NSCLC with PFS of at least 3 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BYSI.US](https://longbridge.com/en/quote/BYSI.US.md)

## Related News & Research

- [BeyondSpring highlights confirmatory Phase 3 DUBLIN-4 trial plan for plinabulin in post-ICI NSCLC](https://longbridge.com/en/news/297642398.md)
- [BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach](https://longbridge.com/en/news/296010507.md)
- [FTH: Oral multi-node inhibition demonstrates strong early efficacy and tolerability in cancer trials](https://longbridge.com/en/news/298617683.md)
- [Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference | VNRX Stock News](https://longbridge.com/en/news/298594142.md)
- [Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases](https://longbridge.com/en/news/298307942.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**